Resistance to angiogenesis inhibitors in renal cell carcinoma

Area of Science:

• Oncology
• Cancer Biology
• Pharmacology

Background:

• Antiangiogenic drugs are standard treatments for renal cell carcinoma (RCC), often used sequentially to extend patient benefit.
• While effective in stabilizing disease, acquired resistance to these therapies is a common clinical challenge.
• Investigating resistance mechanisms is vital due to ongoing clinical trials exploring novel drug combinations and sequences.

Purpose of the Study:

• To explore the mechanisms of primary and acquired resistance to antiangiogenic drugs in renal cell carcinoma.
• To understand how tumors evade therapy through intrinsic pathways or adaptive responses.
• To identify potential targets and strategies for overcoming resistance in RCC treatment.

Main Methods:

• Review of existing literature on antiangiogenic therapy resistance in renal cell carcinoma.
• Analysis of proposed biological pathways and molecular mechanisms driving tumor escape.
• Consideration of preclinical and clinical trial designs for resistance investigation.

Main Results:

• Resistance to antiangiogenic therapy can be primary (non-responsiveness) or acquired over time.
• Primary resistance may stem from redundant angiogenic signaling pathways.
• Acquired resistance often involves tumor-induced upregulation of vascular endothelial growth factor (VEGF) or activation of alternative revascularization pathways (angiogenic switch).

Conclusions:

• Understanding tumor resistance mechanisms is essential for optimizing antiangiogenic drug sequencing and combination therapies in RCC.
• Further research into primary and acquired resistance pathways will inform the development of more effective treatment strategies.
• Rationally designed clinical trials are necessary to elucidate and address resistance to antiangiogenic agents in RCC.